Consensi FDA Approval History
Last updated by Judith Stewart, BPharm on May 2, 2023.
FDA Approved: Yes (Discontinued) (First approved May 31, 2018)
Brand name: Consensi
Generic name: amlodipine and celecoxib
Dosage form: Tablets
Company: Purple Biotech Ltd.
Treatment for: High Blood Pressure, Osteoarthritis
Consensi (amlodipine and celecoxib) is a calcium channel blocker and nonsteroidal anti-inflammatory drug combination for the treatment of both hypertension and pain associated with osteoarthritis.
- On February 9, 2022, Purple Biotech Ltd. announced in a press release that the agreement with the U.S distributor for Consensi had been terminated. It was concluded that commercialization of Consensi was not likely to generate significant revenue and achieve profitability in the near term, so in order to reduce expenses involved in maintaining the product, Consensi would be discontinued.
- The marketing end date for Consensi was July 27, 2022.
Development timeline for Consensi
| Date | Article |
|---|---|
| May 31, 2018 | Approval FDA Approves Consensi (amlodipine and celecoxib) for Treatment of Hypertension and Osteoarthritis Pain |
| Oct 2, 2017 | Kitov Announces Filing by FDA of New Drug Application for KIT-302 |
| Jul 31, 2017 | Kitov Submits New Drug Application to FDA for KIT-302 |
| Jun 26, 2017 | Kitov Updates on KIT-302 New Drug Application |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
